+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tourette's Syndrome Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023 - Product Image

Tourette's Syndrome Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023

  • ID: 4833478
  • Report
  • Region: Global
  • 145 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Eli Lilly and Co.
  • H. Lundbeck AS
  • Mylan NV
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • MORE
Global Tourette’s Syndrome Drugs Market: About this market

The Tourette’s syndrome drugs market analysis considers sales from both antipsychotics and non-antipsychotics products. Our analysis also considers the sales of Tourette’s syndrome drugs in Asia, Europe, North America, and ROW. In 2018, the antipsychotics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the strong therapeutic value of antipsychotics will play a significant role in the antipsychotics segment to maintain its market position. Also, our global Tourette’s syndrome drugs market report looks at factors such as growing awareness about Tourette’s syndrome, regulatory incentives, and its morbid nature of disease. However, adoption of non-pharmacological therapies, difficulty in diagnosis, and drug in late-stage clinical trials may hamper the growth of the Tourette’s syndrome drugs industry over the forecast period.

Global Tourette’s Syndrome Drugs Market: Overview

Morbid nature of the disease

As Tourette’s syndrome is basically a neurodevelopment syndrome that produces results in repetitive, involuntary movements and unwanted sounds - collectively termed as tics - it . This syndrome is often accompanied by other syndromes disorders such as attention deficit hyperactivity disorder ADHD and obsessive-compulsive disorderOCD. This can result in ese condition leads to poor psychological functioning and quality of life. Therefore, a supportive environmental, behavioral and emotional support is necessary to overcome the challenges faced by the patients. Several non-antipsychotic and atypical antipsychotic drugs, such as quetiapine, olanzapine, risperidone, and aripiprazole are available at low cost that helps in suppressing tics in patients with Tourette’s syndrome. This low cost and morbid nature of disease will lead to the expansion of the global Tourette’s syndrome drugs market at a CAGR of almost 5% during the forecast period.

Development of novel therapeutics

Several pharmaceutical companies and researchers are focusing on the development of novel drugs that correct the dopaminergic disturbances responsible for motor and vocal tics in Tourette’s syndrome patients. For instance, ecopipam, a first-in-class drug developed by Emalex Biosciences, selectively blocks the actions of the neurotransmitter dopamine at the D1 receptor pediatric patients. Also, Therapix Biosciences is evaluating the efficacy and safety of THX-110, a drug candidate platform for the treatment of symptoms related to Tourette’s syndrome. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global Tourette’s syndrome drugs market is fragmented. The robust vendor analysis is designed to help clients improve their market position and in In line with this, this report provides a detailed analysis of several leading Tourette’s syndrome drugs manufacturers, that include AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., H. Lundbeck AS, Johnson & Johnson Services Inc., Mylan NV, Otsuka Holdings Co. Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.

Also, the Tourette’s syndrome drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Eli Lilly and Co.
  • H. Lundbeck AS
  • Mylan NV
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Antipsychotics - Market size and forecast 2018-2023
  • Non-antipsychotics - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Development of novel therapeutics
  • Increasing strategic alliances
  • Growing number of research studies to understand genetic root cause of Tourette’s syndrome
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Co.
  • H. Lundbeck AS
  • Johnson & Johnson Services Inc.
  • Mylan NV
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Antipsychotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antipsychotics - Year-over-year growth 2019-2023 (%)
Exhibit 22: Non-antipsychotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Non-antipsychotics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: AstraZeneca Plc - Vendor overview
Exhibit 49: AstraZeneca Plc - Business segments
Exhibit 50: AstraZeneca Plc - Organizational developments
Exhibit 51: AstraZeneca Plc - Geographic focus
Exhibit 52: AstraZeneca Plc - Key offerings
Exhibit 53: AstraZeneca Plc - Key customers
Exhibit 54: Boehringer Ingelheim International GmbH - Vendor overview
Exhibit 55: Boehringer Ingelheim International GmbH - Business segments
Exhibit 56: Boehringer Ingelheim International GmbH - Organizational developments
Exhibit 57: Boehringer Ingelheim International GmbH - Geographic focus
Exhibit 58: Boehringer Ingelheim International GmbH - Segment focus
Exhibit 59: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 60: Boehringer Ingelheim International GmbH - Key customers
Exhibit 61: Eli Lilly and Co. - Vendor overview
Exhibit 62: Eli Lilly and Co. - Business segments
Exhibit 63: Eli Lilly and Co. - Organizational developments
Exhibit 64: Eli Lilly and Co. - Geographic focus
Exhibit 65: Eli Lilly and Co. - Segment focus
Exhibit 66: Eli Lilly and Co. - Key offerings
Exhibit 67: Eli Lilly and Co. - Key customers
Exhibit 68: H. Lundbeck AS - Vendor overview
Exhibit 69: H. Lundbeck AS - Business segments
Exhibit 70: H. Lundbeck AS - Organizational developments
Exhibit 71: H. Lundbeck AS - Geographic focus
Exhibit 72: H. Lundbeck AS - Key offerings
Exhibit 73: H. Lundbeck AS - Key customers
Exhibit 74: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 75: Johnson & Johnson Services Inc. - Business segments
Exhibit 76: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 77: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 78: Johnson & Johnson Services Inc. - Segment focus
Exhibit 79: Johnson & Johnson Services Inc. - Key offerings
Exhibit 80: Johnson & Johnson Services Inc. - Key customers
Exhibit 81: Mylan NV - Vendor overview
Exhibit 82: Mylan NV - Product segments
Exhibit 83: Mylan NV - Organizational developments
Exhibit 84: Mylan NV - Geographic focus
Exhibit 85: Mylan NV - Segment focus
Exhibit 86: Mylan NV - Key offerings
Exhibit 87: Mylan NV - Key customers
Exhibit 88: Otsuka Holdings Co. Ltd. - Vendor overview
Exhibit 89: Otsuka Holdings Co. Ltd. - Business segments
Exhibit 90: Otsuka Holdings Co. Ltd. - Organizational developments
Exhibit 91: Otsuka Holdings Co. Ltd. - Geographic focus
Exhibit 92: Otsuka Holdings Co. Ltd. - Segment focus
Exhibit 93: Otsuka Holdings Co. Ltd. - Key offerings
Exhibit 94: Otsuka Holdings Co. Ltd. - Key customers
Exhibit 95: Pfizer Inc. - Vendor overview
Exhibit 96: Pfizer Inc. - Business segments
Exhibit 97: Pfizer Inc. - Organizational developments
Exhibit 98: Pfizer Inc. - Geographic focus
Exhibit 99: Pfizer Inc. - Segment focus
Exhibit 100: Pfizer Inc. - Key offerings
Exhibit 101: Pfizer Inc. - Key customers
Exhibit 102: Sun Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 103: Sun Pharmaceutical Industries Ltd. - Business segments
Exhibit 104: Sun Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 105: Sun Pharmaceutical Industries Ltd. - Geographic focus
Exhibit 106: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibit 107: Sun Pharmaceutical Industries Ltd. - Key customers
Exhibit 108: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 109: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 114: Validation techniques employed for market sizing
Exhibit 115: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Eli Lilly and Co.
  • H. Lundbeck AS
  • Mylan NV
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global Tourette’s syndrome drugs market: AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., H. Lundbeck AS, Johnson & Johnson Services Inc., Mylan NV, Otsuka Holdings Co. Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of novel therapeutics.”

According to the report, one of the major drivers for this market is the morbid nature of the disease.

Further, the report states that one of the major factors hindering the growth of this market is the difficulty in diagnosis.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Co.
  • H. Lundbeck AS
  • Johnson & Johnson Services Inc.
  • Mylan NV
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Ind
Note: Product cover images may vary from those shown
Adroll
adroll